Free Trial
NASDAQ:LNTH

Lantheus Q2 2025 Earnings Report

Lantheus logo
$79.21 -0.41 (-0.51%)
Closing price 07/3/2025 03:33 PM Eastern
Extended Trading
$79.21 0.00 (0.00%)
As of 07/3/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantheus EPS Results

Actual EPS
N/A
Consensus EPS
$1.65
Beat/Miss
N/A
One Year Ago EPS
N/A

Lantheus Revenue Results

Actual Revenue
N/A
Expected Revenue
$389.69 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lantheus Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, July 30, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Lantheus Earnings Headlines

Lantheus Seems Worth The (Very Real) Risks
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Lantheus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lantheus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lantheus and other key companies, straight to your email.

About Lantheus

Lantheus (NASDAQ:LNTH) is a life sciences company specializing in the development, manufacture and commercialization of innovative diagnostic imaging agents and radiopharmaceutical products. The company focuses on molecular imaging and targeted radiotherapeutics, seeking to advance precision medicine through noninvasive technologies that help clinicians detect, diagnose and treat disease.

Its product portfolio spans several key imaging modalities and therapeutic areas. Lantheus markets Definity, an ultrasound contrast agent used in echocardiography, and operates the TechneLite™ generator system for producing technetium-99m, a critical isotope in nuclear medicine. The company’s precision diagnostics franchise includes Gallium Ga-68 DOTATATE injection (NETSPOT®) for imaging neuroendocrine tumors and piflufolastat F-18 injection (PYLARIFY®) for PET scanning of prostate cancer. On the therapeutic side, Lantheus offers iobenguane I-131 injection (AZEDRA®) for the treatment of rare neuroendocrine tumors, reflecting its growing commitment to radiotherapeutics.

Originally founded in the mid-20th century, Lantheus entered its current form following the 2006 acquisition of DuPont’s medical imaging business. The company accelerated its expansion into radiopharmaceuticals with the 2021 acquisition of Progenics Pharmaceuticals, adding both diagnostic and therapeutic assets to its pipeline. Under the leadership of President and Chief Executive Officer Michael M. Weingarten and a seasoned management team, Lantheus has pursued strategic investments in research, manufacturing and regulatory capabilities.

Lantheus maintains a global footprint with manufacturing facilities, research centers and distribution networks across North America and Europe. Its products are supplied to academic medical centers, hospitals and specialty clinics, and the company continues to invest in scalable production and new product development to broaden access to molecular imaging and targeted therapy solutions worldwide.

View Lantheus Profile

More Earnings Resources from MarketBeat